Clinical bottom line
Personalized antihypertensive therapy, incorporating drug concentration monitoring, patient-specific feedback, and psychosocial factors, shows promise in improving blood pressure control and cardiovascular outcomes in patients with resistant hypertension. Home blood pressure monitoring further refines risk stratification and guides tailored treatment adjustments. However, evidence remains preliminary, and implementation challenges persist, underscoring the need for individualized, multidisciplinary approaches.
What the evidence shows
Resistant hypertension, defined as blood pressure uncontrolled despite three or more antihypertensive agents, poses significant cardiovascular risk. Rubin et al. (2024) proposed integrating antihypertensive drug concentration measurements with personalized feedback and psychosocial assessments to optimize treatment adherence and efficacy. Their approach addresses common barriers such as nonadherence and variable pharmacokinetics.
Peeters et al. (2024) responded by emphasizing the feasibility and potential benefits of this integrated strategy, highlighting the importance of combining objective drug level data with behavioral interventions to improve outcomes.
Cardoso et al. (2021) demonstrated that home blood pressure measurements provide superior prognostic information compared to office readings in resistant hypertension, predicting adverse cardiovascular events and mortality. This supports the use of home monitoring to personalize therapy intensity and timing.
Mohammad Suleiman et al. (2025) compared antihypertensive therapy outcomes in diabetic adults with resistant hypertension, underscoring the need for tailored regimens considering comorbidities to reduce cardiovascular risk effectively.
HERMIDA et al. (2004) showed that timing of antihypertensive medication influences ambulatory blood pressure patterns, suggesting chronotherapy as a component of personalized treatment.
Older foundational work by Giles et al. (1992) reminds clinicians that not all antihypertensives confer equal cardiovascular risk reduction, reinforcing the rationale for individualized drug selection.
Caveats and uncertainty
Most evidence derives from observational studies, expert opinion, or small cohorts; large randomized trials are lacking.
Measuring drug concentrations is not yet widely available or standardized in clinical practice.
Psychosocial factors are complex and may require multidisciplinary resources not universally accessible.
Home blood pressure monitoring depends on patient adherence and accurate measurement techniques.
Optimal algorithms for integrating these personalized data streams remain to be validated.
How this may change practice
Clinicians managing resistant hypertension should consider comprehensive evaluation including adherence assessment, drug level monitoring where feasible, and psychosocial screening.
Incorporation of home blood pressure monitoring can enhance risk stratification and guide therapy adjustments.
Personalized treatment plans addressing pharmacologic, behavioral, and timing factors may improve blood pressure control and reduce cardiovascular events.
Multidisciplinary collaboration including pharmacists, behavioral specialists, and nurses is encouraged.
Future guideline updates may incorporate personalized approaches as evidence matures.